U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Go back to U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.63 -4.36 (2.89%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $150.99 | 52 Week High | $108.63 | |||
| Open | $146.98 | 52 Week Low | $71.39 | |||
| Day High | $148.65 | P/E | 81.01 | |||
| Day Low | $145.45 | EPS | $1.81 | |||
| Volume | 1,615,053 | |||||
